Dataset Information


Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

ABSTRACT: BACKGROUND: Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD). METHODS: In this study, we evaluated DPYD promoter methylation through quantitative methylation-specific PCR and screened DPYD for large intragenic rearrangements in peripheral blood from 45 patients with gastrointestinal cancers who developed severe 5-FU toxicity. DPYD promoter methylation was also assessed in tumor tissue from 29 patients RESULTS: Two cases with the IVS14+1G > A exon 14 skipping mutation (c.1905+1G > A), and one case carrying the 1845 G > T missense mutation (c.1845G > T) in the DPYD gene were identified. However, DPYD promoter methylation and large DPYD intragenic rearrangements were absent in all cases analyzed. CONCLUSIONS: Our results indicate that DPYD promoter methylation and large intragenic rearrangements do not contribute significantly to the development of 5-FU severe toxicity in gastrointestinal cancer patients, supporting the need for additional studies on the mechanisms underlying genetic susceptibility to severe 5-FU toxicity.

SUBMITTER: Savva-Bordalo J 

PROVIDER: S-EPMC2940808 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6571425 | BioStudies
2013-01-01 | S-EPMC3602211 | BioStudies
2012-01-01 | S-EPMC3547229 | BioStudies
2015-01-01 | S-EPMC4425114 | BioStudies
2014-01-01 | S-EPMC4071869 | BioStudies
2019-01-01 | S-EPMC6867961 | BioStudies
2016-01-01 | S-EPMC5093042 | BioStudies
2020-01-01 | S-EPMC7564232 | BioStudies
1000-01-01 | S-EPMC5575263 | BioStudies
2016-01-01 | S-EPMC4738010 | BioStudies